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Background. Cellular immunity plays a key role in determining the outcome of hepatitis C virus (HCV) infection, although the
majority of infections become persistent. The mechanisms behind persistence are still not clear; however, the primary site of
infection, the liver, may be critical. We investigated the ability of CD8+ T-cells (CTL) to recognise and kill hepatocytes under
cytokine stimulation. Methods/Principle Findings. Resting hepatocytes cell lines expressed low levels of MHC Class I, but
remained susceptible to CTL cytotoxicity. IFN-a treatment, in vitro, markedly increased hepatocyte MHC Class I expression,
however, reduced sensitivity to CTL cytotoxicity. IFN-a stimulated hepatocyte lines were still able to present antigen and
induce IFN-c expression in interacting CTL. Resistance to killing was not due to the inhibition of the FASL/FAS- pathway, as
stimulated hepatocytes were still susceptible to FAS-mediated apoptosis. In vitro stimulation with IFN-a, or the introduction of
a subgenomic HCV replicon into the HepG2 line, upregulated the expression of the granzyme-B inhibitor–proteinase inhibitor
9 (PI-9). PI-9 expression was also observed in liver tissue biopsies from patients with chronic HCV infection. Conclusion/
Significance. IFN-a induces resistance in hepatocytes to perforin/granzyme mediate CTL killing pathways. One possible
mechanism could be through the expression of the PI-9. Hindrance of CTL cytotoxicity could contribute to the chronicity of
hepatic viral infections.
Citation: Willberg CB, Ward SM, Clayton RF, Naoumov NV, McCormick C, et al (2007) Protection of Hepatocytes from Cytotoxic T Cell Mediated Killing
by Interferon-Alpha. PLoS ONE 2(8): e791. doi:10.1371/journal.pone.0000791
INTRODUCTION
The hepatitis C virus (HCV) is estimated to infect over 100
million people world wide, causing persistent infection in the
majority [1]. The cellular immune response is thought to play
a major role in the clearance and control of the virus and failure
of cellular responses to HCV is a major factor for chronic viral
persistence [2–4]. The reasons behind this failure are still
unclear. One possibility could be the site of infection, the liver
itself.
The importance of the liver as a unique site of antigen
presentation was initially highlighted by Calne in 1969 [5,6].
Many of the liver resident cells have been implicated in the
regulation of immune responses, including both liver sinusoidal
epithelial cells [7] and hepatocytes [8]. However, the precise
mechanisms remain to be fully clarified.
Under constant exposure to foreign antigen from the gut, the
liver needs to resist or suppress misdirected immune responses.
Hepatocytes represent the primary site for replication of several
hepatotropic viruses, including HCV. Human hepatocyte expres-
sion of MHC Class I has been well documented as low to absent in
vivo [9–13]. Therefore, the ability of hepatocytes to present antigen
and act as CTL targets may differ from that of other cells.
Understanding T cell-hepatocyte interactions is therefore crucial
in defining the mechanisms behind the clearance or persistence of
hepatic viral infection.
CTL clearance of viral infection can occur by either the
destruction of the infected cells or the up-regulation of antiviral
mechanisms within the cells by the expression of IFN-c. The
destruction of infected cells by CTLs can be mediated by either
receptor-mediated induction of apoptosis or via the perforin/
granzyme pathway. IFN-c mediated pathways are thought to
dominate over cytotoxicity in the clearance of hepatotropic
viruses [14,15], although the mechanisms behind this are not yet
clear.
In this study we the modelled CD8+ T cell–hepatocytes using
both a traditional hepatocellular carcinoma derived hepatocyte
cell line, HepG2, as well as in vitro immortalised primary human
hepatocyte lines (HHL -6, -16 and -17), previously described
[16]. Furthermore, as both HCV and HBV specific CD8+ T
Cell responses during chronic infections are weak and
potentially dysfunctional [3,17–19], we generated short term
CD8+ T cell lines specific for non-hepatotrophic viruses CMV
and EBV whose responses are well documented, robust and
reproducible. Therefore, CD8+ T cell/hepatocyte interactions
were assessed using model hepatocyte cell lines pulsed with the
specific cognate peptides and assayed using well-defined T cell
populations.
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RESULTS
Hepatocytes as CTL Targets
CTL recognise potential targets through TCR-MHC Class I
interactions. Human hepatocyte expression of MHC Class I has
been well documented as low to absent in vivo [9–13]. Therefore,
hepatocytes may represent poor CTL targets and hinder the
ability of CTL to clear hepatotrophic viruses, such as HCV. This
may contribute to the chronicity of such infections.
MCH Class I expression can be modulated by cytokine
stimulation. IFN-a is known to induce the up-regulation of
MHC Class I on many cell types including hepatocytes [20].
Moreover, IFN-a represents a major component of the current
HCV treatment, as well as being expressed by cells upon viral
infection as part of the innate cellular response.
Stimulation of the hepatocellular carcinoma cell line, HepG2,
and the novel immortalised human hepatocyte lines (HHL) -6, -16
and -17 (data not shown) with IFN-a resulted in increased MHC
Class I expression, figure 1 A–B. However, this was not
accompanied by an increase in susceptibility to CTL killing,
figure 1 C–D, assessed using the flow cytometry based cytotoxicity
VITAL assay [21]. IFN-a treatment rendered the hepatocytes less
susceptible to CTL cytotoxicity in a dose dependent manner
(Figure 1C). As this phenomenon was also seen in the
immortalised HHLs this was not a mechanism of carcinoma
escape (Figure 1 D); although it might be a pathway utilised by
hepatocellular carcinomas. However, the same effect could not be
induced in a B cell line (Figure 2), nor was this observed in
keratinocytes (Dr Ogg and Dr Black, Oxford, personal commu-
nications).
Antigen Presentation
In order to deduce the mechanism behind the reduced
susceptibility of hepatocyte lines to CTL killing, the ability of the
hepatocytes to present antigen was first examined. CTL interac-
tions with target cells results in both cytotoxicity and the
production of IFN-c. In order to confirm that IFN-a stimulation
did not alter the ability of the hepatocyte lines to present antigen,
the levels of IFN-c induced within interacting CTL was analysed.
IFN-c expression in CTL incubated with IFN-a stimulated and
Figure 1. IFN-a reduces hepatocyte sensitivity to CTL cytotoxicity. Hepatocytes have been described as expressing low to no MHC Class I. As
expected, IFN-a treatment increased the levels of MHC Class I on HepG2 (A) and HHL (B); filled curve represents an isotype control, the solid line
represents the MCH Class I expression. C) HepG2 cells were stimulated for 16 hours with a serial dilution of IFN-a at 0 IU/ml (closed circles), 10 IU/ml
(open diamonds), 100 IU/ml (open squares), and 1000 IU/ml (open inverted triangles), prior to cytotoxicity assay with the CTL line 2. Treatment with
IFN-a reduced the HepG2 cells sensitivity to CTL cytotoxicity in a dose dependent manner. D) This phenomenon was also found with the novel
human hepatocyte cell lines (HHL). HHL-17 cells were either left untreated (closed circles) or stimulated for 16 hours with 1000 IU/ml (open inverted
triangles) prior to co-incubation with the CTL line 1.
doi:10.1371/journal.pone.0000791.g001
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un-stimulated hepatocyte cell lines revealed no detectable
difference in the ability of the HepG2 cell line to present antigen
(Figure 3). This could also be reproduced with the HHLs, (data not
shown).
These data implied that the mechanism behind the reduced
killing lay in the ability of the hepatocyte lines to resist CTL
cytotoxicity.
Resistance was Independent of FASL-Induced
Apoptosis
Several studies have described hepatocyte sensitivity to FASL-
induced apoptosis, both in vitro and in vivo [22–26]. The Bcl protein
family represent potent inhibitors of the FASL-mediated apoptotic
pathway [27]. The expression of Bcl-2 as well as FAS on the
hepatocyte cell lines +/2 IFN-a stimulation was analysed
(Figure 4). IFN-a stimulation showed no effect on FAS expression
on any of the hepatocyte cell lines tested. The expression of Bcl-2
was not seen in all the hepatocyte cell lines. Where Bcl-2 was
undetectable IFN-a stimulation had no effect. However, the
HepG2 cell line, where Bcl-2 levels were low, IFN-a stimulation
led to the reduction of Bcl-2. The decrease in Bcl-2 expression in
the IFN-a stimulated cells suggested this molecule is not
responsible for resistance to CTL-killing seen.
Recombinant FASL (rFASL) with a FLAG motif was used to
examine the complete apoptotic pathway in isolation. rFASL was
cross-linked on the cell surface by the use of an anti-FLAG
antibody, thereby inducing apoptosis. As previously, hepatocyte
cell lines were stimulated for 16 hours with IFN-a at varying
concentrations prior to incubation with rFASL. IFN-a stimulation
of the HepG2 cell line had no protective affect against FASL-
induced apoptosis. This was confirmed by Annexin V binding
combined with propidium iodine (P.I) incorporation, and by the
cytosolic presence of the activated form of caspase 3 (Figure 5A).
The duration of the rFAS-FASL interactions also revealed no
difference between IFN-a stimulated and un-stimulated cells
(Figure 5B).
FAS2/2 Human Hepatocyte Line
The lack of resistance to FASL-induced apoptosis in IFN-
a stimulated hepatocytes was further confirmed in the human
hepatocyte line, HHL-16, which was shown to be FAS negative
(Figure 6A). Consistent with this, rFASL did not induce apoptosis
in this cell line (data not shown). Un-stimulated HHL-16 cells were
readily killed by CTL (Figure 6B). However, after stimulation with
IFN-a, at either 100 IU/ml or 1000 IU/ml, killing could only be
observed at the higher E:T ratio of 10:1. Combined with the
results above, this suggested that resistance to CTL cytotoxicity is
mediated through other pathways, such as the perforin/granzyme
pathway.
Analysis of Resistance to Granzyme B
Recently, surface expressed cathepsin B has been shown to prevent
the action of perforin and thereby preventing the release of
granzymes into the target cell cytosol [28]. FACS analysis of the
hepatocyte cell lines did not reveal surface expression of cathepsin
B, even after IFN-a stimulation (data not shown).
The granzyme proteinase family consists of many proteinases of
which granzyme A and B are thought to play the major roles in
inducing target cell apoptosis. Currently, only two naturally
expressed inhibitors to these granzymes have been identified.
Serine proteinase inhibitor (PI) -9 is known to be a specific
inhibitor of granzyme B, while the action of granzyme A has been
shown to be inhibited by the pancreatic secretary trypsin inhibitor
(PSTI) [29,30]. Both these inhibitors have been shown to be
expressed in rat and murine hepatocytes, as well as human
hepatocellular carcinoma lines [31,32]. RT-PCR confirmed that
the HHLs, as well as the hepatocellular carcinoma line, HepG2,
were able to up-regulate PI-9 after IFN-a stimulation (Fig. 7A–B).
Thus, providing the first evidence that PI-9 expression is not
limited in humans to carcinoma derived cell lines.
To address whether the induction of resistance to killing and the
up-regulation of PI-9 were IFN-a specific, we repeated these
experiments using alternative inflammatory stimuli: IFN-c and IL-
1b. Both IFN-c and IL-1b stimulation of HepG2 cell line led to an
up-regulation of PI-9 (Fig. 8A), which were accompanied by
resistance to CTL killing (Fig. 8B). Furthermore, PI-9 expression
could be induced in the HepG2 cell line through infection with
a baculovirus that delivered a replicating sub-genomic replicon
[33,34] (Fig. 8C), suggesting the induction of PI-9 expression is not
limited to exogenous cytokine stimulation.
PI.-9 expression in vivo
Finally, to address whether PI-9 expression was an in vitro artefact,
liver specimens from diagnostic liver biopsies were stained. PI-9
expression was observed in all sections from patients with HCV
cirrhosis (n = 3) (Fig. 9). Similar data was obtained from frozen
unfixed liver specimens, (data not shown). These data showed for
the first time PI-9 expression in primary human hepatocytes in vivo
during chronic HCV infection.
Figure 2. IFN- treatment did not protect a B-cell line. Treatment of
a BCL with 1000 IU/ml IFN-a (open inverted triangles) prior to the
cytotoxicity assay, did not reduce CTLs ability to kill the treated BCL
compared to the untreated BCL (closed circles).
doi:10.1371/journal.pone.0000791.g002
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DISCUSSION
The ability of hepatocytes to act as good targets for CTLs is crucial
for the clearance of heptotrophic viral infections. Central to the
success of the CTL responses is the recognition of infected cells
through TCR-MHC Class I interactions. The low or absent levels
of MHC Class I on hepatocytes have be described in vivo and could
potentially contribute to the failure of the CTL response to clear
HCV [9–13]. This study set out to explore this interaction and the
influence of up-regulation of MHC Class I by IFN-a.
As expected IFN-a stimulation up-regulated MHC Class I on
the hepatocyte derived cell lines. However, unexpectedly this was
not accompanied by an increase in sensitivity to CTL cytotoxicity.
The IFN-a induced resistance to CTL cytotoxicity was not
mediated through alteration of the antigen presentation pathway,
as stimulated hepatocyte cell lines were still able to induce IFN-c
expression in CTL. Neither was the resistance due to an inhibition
of the FASL-apoptotic pathway. However, IFN-a induced re-
sistance to CTL cytotoxicity was accompanied by the expression of
the granzyme B inhibitor–proteinase inhibitor 9 (PI-9).
Hepatocytes have been described by several groups to be highly
sensitive to FASL-induced apoptosis, and thus FASL has been
presented as the main pathway by which lymphocytes kill
hepatocytes [24–26]. Jin et al. described the ability of liver
infiltrating lymphocytes to kill hepatocytes to be predominantly
FASL-mediated [35]. If the granzyme pathway is inhibited by
cytokine-induction of PI-9 expression within hepatocytes, then the
observed sensitivity to FASL could potentially be due to
a desensitisation to granzyme B induction of apoptosis.
Granzyme mediated apoptosis primarily involves granzymes A
and B. Both of these granzymes have natural inhibitors, the
pancreatic secretary trypsin inhibitor (PSTI) and serine protease
inhibitor-9 (PI-9) [29,30]. Both inhibitors have been shown to be
expressed in hepatocytes [31,32]. Here the expression of PI-9 in the
hepatocellular carcinoma cell line, HepG2, as well as in immorta-
lised primary human hepatocyte lines (HHL), was confirmed.
Moreover, PI-9 was observed for the first time in vivo, in liver biopsies
Figure 4. IFN- treatment does not induce Bcl-2 expression.
Hepatocyte expression of the anti-apoptotic protein Bcl-2 was assessed
by FACS. HHL-17 cells were stimulated with IFN-a at either 0 IU/ml,
100 IU/ml or 1000 IU/ml for 16 hours. Un-stimulated hepatocytes
expressed low levels of Bcl-2 (MFI of 6.08), while those treated with
either 100 IU/ml or 1000 IU/ml of IFN-a lost expression (MFI of 3.99 and
3.42 respectively); filled curves represent an isotype control, and solid
lines represent the Bcl2 staining.
doi:10.1371/journal.pone.0000791.g004
Figure 3. IFN-a stimulated hepatocytes are still able to act as APCs to CTL. HepG2 cells were stimulated for 16 hours with 1000 U/ml IFN-a, or left
untreated. The cells were then pulsed with the specific cognate peptide and washed, prior to co-incubation with the CTL line 2. As controls non-
peptide-pulsed cells were used, or all PBMC were peptide pulsed or stimulated with PMA/ionomycin. A) The raw FACS data showing the CD8+
expression on the y axis’s and IFN-c on the x axis’s. B) The percentage secretion data from such experiment. HepG2p represents peptide pulsed cells
with or without IFN-a stimulation as indicated. This data is representative of 4 such experiments.
doi:10.1371/journal.pone.0000791.g003
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from chronically infected individuals. However, the precise contri-
bution PI-9 makes to hepatocyte resistance to CTL cytotoxicity is yet
to be clarified. As IFN-a up-regulates a large number of genes, it is
probable that other proteins could also be involved in hepatocyte
resistance to CTL killing. Knockdown experiments will dissect the
specific contribution PI-9 or other inhibitors play.
Regardless of the precise mechanisms behind the hepatocyte
resistance to CTL killing, the ability of the hepatocytes to resist
killing and promote IFN-c release could, if this occurs in vivo, lead
to the skewing of a CTL response towards cytokine-mediated
clearance of a hepatic viral infection and away from cytotoxic
mechanisms. Such a response has been clearly shown in HBV and
LCMV, as well as Duck HBV and Malaria infections where IFN-c
has been shown to be responsible for the clearance of these viruses
as opposed to cytopathic mechanisms [14,15,36–38]. The
evolutionary advantage of such a cytoprotective mechanism is
not clear, but presumably relates to protection against immuno-
pathology. Very high-level CD8+ T cell responses against a virus
infecting large numbers of hepatocytes could readily lead to severe
liver damage [39]. This risk of antigen mediated or bystander
cellular destruction may be minimised through this pathway.
The ability to resist CD8+ T cell cytotoxicity may be a double-
edged sword as such a mechanism could be utilised by infecting
viruses to evade CD8+ T cell responses. As long as the virus is able to
resist the innate cellular antiviral mechanisms such as PKR,MxA and
RNase L, then clearance could only be mediated via the slower FASL
pathway and thus contributing to the persistence of the infection.
Further understanding of the mechanisms behind the cytokine-
induce hepatocyte resistant to CTL cytotoxicity could lead to
novel drug targets, as well as being of potential diagnostic use.
However, the full details of the T-cell hepatocyte interaction, while
critical to the outcome of many infections, are only just beginning
to be addressed.
MATERIALS AND METHODS
Cell lines
HepG2 cells (ECACC) and Human Hepatocyte Lines (HHL),
generated by Clayton et al [16] -6, -16, -17, were cultured in
MEME media (Sigma) plus supplements. Cultures were split once
they reached 80% confluence. An EBV transformed B Cell Line
(BCL) was cultured in RPMI media (Sigma) with supplements.
Isolation of Peripheral Blood Mononuclear Cells (PBMC):
PBMCs were isolated from whole blood collected and mixed with
either heparin or EDTA, and separated by density gradient
centrifugation over lymphoprep (Nycomed, UK).
CTL lines
Lines were generated from the PBMC of healthy donors.
Approximately 106106 cells were pulsed with 10 mM specific
peptide solution for 1 hour before culturing for 12 –14 days in
medium containing IL-2 (50 U/ml). Freshly generated cytotoxic
T-cell lines were used in all the assays and were matched to the
hepatocyte lines tissue types. CTL lines were generated to match
Figure 5. IFN-a treated hepatocytes remain susceptible to FASL-induced apoptosis. Aii) Induction of apoptosis by FASL was assessed across
a concentration range. HepG2 cells, either stimulated with IFN-a (1000 IU/ml) (closed inverted triangles) or left un-stimulated (open diamonds), were
incubated with cross-linked rFASL at concentrations ranging from 0.1 pg/ml to 2 mg/ml. Apoptosis was assessed by Annexin V binding and
propidium iodine (P.I) incorporation. Ai) Raw FACS data is shown. Bii) HepG2 cells, either un-stimulated (open and closed circles), stimulated with
100 IU/ml (open and closed squares) IFN-a or 1000 IU/ml (open and closed inverted triangles) IFN-a, were incubated with 1 mg/ml (left, open
symbols) or 2 mg/ml (right, closed symbols) cross-linked rFASL over a time course of up to 6 hours. Apoptosis was assessed by the cytosolic presence
of the activated form of caspase 3. Bi) Raw FACS data.
doi:10.1371/journal.pone.0000791.g005
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target cells based on their HLA expression. The HHLs expressed
HLA-B35 and therefore lines were generated against the HLA-
B35 restricted CMV peptide (IPSINVHHY)–labelled as CTL Line
1. As well as expressing HLA-B35 the HepG2 cell line also
expressed HLA-A2. CTL lines restricted to the HLA-A2 restricted
EBV peptide (GLCTLVAML) were generated and labelled as
CTL Line 2.
Cytokine Stimulation
Cells were seeded in 6 well plates and allowed to settle for
24 hours prior to stimulation for 16 hours under normal culturing
conditions. IFN-a (Roche, UK) was used at 1000 IU/ml unless
otherwise stated, IFN-c (R&D, UK) was used at 100 IU/ml, and
IL-1b (R&D, UK) was used at 50 ng/ml.
Cytotoxicity assay (VITAL assay) and rFASL-induced
apoptosis
CTL cytotoxicity assays were based on the VITAL assay described
by Hermans et al. [21] and the FATAL assay described by Sheehy
et
Figure 6. A FAS negative hepatocyte line showed almost complete
resistance to CTL killing. A) The lack of FAS expression on the HHL-16
cells was confirmed by FACS analysis in both un-stimulated and IFN-
a stimulated cells. FAS expression was negative under both conditions,
mean fluorescence intensity of 4.60 and 4.34 respectively (open curves),
and never higher than an isotype control (filled curve). B) Under normal
conditions (closed squares) the HHL-16 cells were able to act as targets for
CTL cytotoxicity after 4 hours co-incubation. However, stimulation with
IFN-a, either at 100 IU/ml (closed triangles) or at 1000 IU/ml (closed
inverted triangle), reduced killing below 10% even at the higher E:T ratio.
doi:10.1371/journal.pone.0000791.g006
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al. [40]. Cognate peptides were pulsed on to the target cells at
10 mg/ml.
FASL-induced apoptosis
Stimulated or un-stimulated cells were seeded into a 96 U-bottom
plate, to which 2 mg/ml of recombinant FAS ligand (FASL)-FLAG
(kindly donated by Professor G Screaton, Oxford) was added. This
was cross-linked using an anti-FLAG antibody (Abcam, UK), and
incubated for 4 hours (unless otherwise indicated) at 37uC.
Apoptosis was measured by Annenix V-propidium iodide (BD
Pharmigen) staining, or by staining for intracellular activated
caspase 3 (as described below).
Antibodies and Staining, Intercellular Cytokine
Staining (ICS)
MHC Class I and CD8 Staining: Cells were harvested and were
washed with PBS prior to staining with the anti-MHC Class I (BD
Pharmingen, Oxford, UK) or CD8 (BD Pharmingen, Oxford,
UK) antibody for 20 minutes at 4uC. For PI-9 (clone 7D8,
Stratech Scientific) and IFN-c (BD Pharmigen, Oxford, UK), cell
surface stains were first conducted prior to permeabilisation with
BD-PERM (BD Pharmingen, Oxford, UK). The staining for
intracellular proteins was then performed using appropriate
antibodies as described above.
Antigen Presentation Assay
CTL effector (E) cells were stimulated by addition of the specific
peptide, target (T) cells pulsed with the specific peptide (E:T 10:1),
or by PMA (10 ngm/ml) ionomycin (1 mg/ml) (Sigma). The cells
were incubated for 1 hour at 37uC before the addition of Golgi
StopTM (BD Pharmingen). The cells were then left for a further
4 hours at 37uC before staining for CD8 and IFN-c (as described
above).
Immunohistology
The expression of PI-9 in liver tissue was detected by
immunostaining using monoclonal PI- 9 antibody (Stratech
Scientific, Soham, UK) at 10 mg/ml as a primary antibody and
Figure 7. Expression of the granzyme B inhibitor, serine proteinase inhibitor 9 (PI-9). A) RT-PCR revealed that IFN-a stimulated cells, HepG2 and
HHL-9 cells, were able to upregulate PI-9. GAPDH expression was analysed as a positive control. Bi and ii) This was confirmed by FACS analysis as
described in the methods and materials. Upregulation of PI-9 was shown to be dose dependent.
doi:10.1371/journal.pone.0000791.g007
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Dako EnVision detection kit (DAKO, Ely, UK). All sections were
stained in parallel with an unrelated primary antibody (MR12) to
provide a negative isotype control. Formalin-fixed, paraffin-
embedded liver biopsy specimens from 3 HCV patients were
obtained from the archive of the Department of Pathology at the
John Radcliffe Hospital, Oxford, UK. Table 1 shows the patient
clinical data. Informed written patient consent was obtained for
each biopsy, which were taken for clinical staging of the disease.
Ethical approval for the study was obtained from the local ethical
review panel (COREC) and the protocols conformed to the ethical
guidelines of the 1975 Declaration of Helsinki.
RT-PCR
RNA was extracted from the cells using the RNAeasy kit (Qiagen).
A cDNA library was generated using oligo-T primers. PI-9 mRNA
was amplified using Forward- CTGCCCTGGCCATGGTTCT-
CCTA and Reverse-CTGGCCTTTGCTCCTCCTGGTTTA
primers, for 32 cycles with an annealing temperature of 64uC.
As a control, GAPDH was amplified from the cDNA library using
Forward- GGTCGGAGTCAACGGATTTG and Reverse- AT-
GAGC CCCAGCCTTCTCCAT primers, for 16 cycles and an
annealing temperature of 61uC.
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